Novo faces shareholder suit over insulin sales disclosures

Novo faces shareholder suit over insulin sales disclosures

Source: 
Biopharma Dive
snippet: 

Shareholders in Novo Nordisk accused the diabetes drugmaker of misleading investors about its insulin drug sales in the U.S., filing a securities lawsuit in Danish court that demands roughly $1.75 billion.